Skip to Main Content
Contribute Try STAT+ Today

After months of deliberation, the Federal Trade Commission approved AbbVie’s (ABBV) $63 billion acquisition of Allergan (AGN), although one commissioner offered a blistering dissent in which he argued the agency’s steps taken to allay antitrust concerns were “narrow, flawed, and ineffective.”

The deal, which was announced nearly a year ago, came as both companies struggled to convince investors they had long-term growth plans. AbbVie felt pressure to diversify as generic competition for its franchise product, the Humira rheumatoid arthritis treatment, is scheduled to arrive in 2023. And Allergan faced new rivals for its best-selling drugs, most notably Botox.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.